ABSTRACT. In this study, we investigated diabetic stage dependent cyclooxygenase-2 (COX-2) immunoreactivity in the dentate gyrus in streptozotocin (STZ)-induced type 1 diabetic rats. The animals were sacrificed at 2, 3 and 4 weeks after STZ treatment. Blood glucose levels were increased after STZ treatment. COX-2 immunoreactivity in dentate gyrus was significantly increased in these regions 3 weeks after STZ treatment and restored to its basal level to 4 weeks after STZ treatment. In contrast, COX-2 immunoreactivity was not changed in CA3 region in all groups. These results suggest that STZ-induced type 1 diabetes transiently, but not permanently, decreased synaptic transmission and plasticity 3 weeks after STZ treatment in the dentate gyrus.
Commonly, there are two types of diabetes mellitus (DM); type 1 DM shows massive loss of pancreatic β cells causing absolute insulin deficiency, while type 2 DM demonstrates relative insulin deficiency in addition to insulin resistance triggered by hyperglycemia which is the key to diabetic clinical symptoms [17] . In brain, neuronal insulin signaling plays an important role in synaptic formation and regeneration of neurons in brain [4] and decreased levels or sensitivity is related with type 1 or 2 DM, respectively. Diabetes impairs the neuronal adaptive ability to oxidative and metabolic stress [15] , and alters hippocampal neurogenesis and neuropathy in dorsal root ganglion [12, 27] . Duration-dependent differences like hippocampal neuronal apoptosis are reported [21] .
For an animal model of type 1 DM, we selected the streptozotocin (STZ) treated rat. STZ interacts with β-cell selectivity via the glucose transporter 2 [20] .
Its toxicity is induced by DNA alkylating activity of its methylnitrosourea moiety, poly-ADP-ribose polymerase overstimulation, and cellular energy depletion [20] .
In many studies including ours, STZ-induced animal models are used for studying the effects of type 1 diabetes mellitus [5, 18, 32] .
Cyclooxygenase (COX), a membrane-bound protein, is involved in inflammation, angiogenesis, colon cancer and Alzheimer's disease [8, 11] , and classified into two types, COX-1 and COX-2. Both isoenzymes convert arachidonic acid into multifunctional prostanoids. COX-2 enzyme is reported as a key player [11] in neuro-inflammation which is involved in most neurodegenerative disorders by eliciting neuronal death and influencing formation of new neurons [9] . In several tissues, mRNA level of COX-2 were studied and FULL PAPER, Anatomy 4 levels in the brain was lowest [24] , but its expression in brain was not the lowest [35] . In brain, COX-2 is involved in normal neuronal function and expressed constitutively at high levels in neurons of the hippocampus, cortex and amygdala, and lower levels in the caudate putamen, thalamus and hypothalamus [34] . Also, the function of COX-2 includes memory consolidation, acquisition and retrieval [26, 29, 31] .
In our previous studies, we observed that the expression of COX-2 and hippocampal neurogenesis is closely associated in a type 2 DM model, the Zucker diabetic fatty rat [13] . However, there are no comparative studies on the expression of COX-2 in the type 1 diabetic animals. In the present study, therefore, we investigated changes in COX-2 immunoreactivity in the hippocampus of STZinduced type 1 diabetic animals. blood glucose levels were monitored and rats with blood glucose levels of >145 mg/dl were utilized for the study and divided into 4 groups.
MATERIALS AND METHODS

Experimental
Check for blood glucose levels: Blood was sampled by a "tail nick" at 9-11 a.m. using a 27 G needle before sacrifice and glucose in blood from a non-fasting state was analyzed by using a blood glucose monitor (SureStep Immunohistochemistry for COX-2: To obtain accurate data for immunohistochemistry, the free-floating sections were carefully processed under the same conditions. The tissue sections were selected between -3.00 ~ -4.08 mm to the bregma in reference to a rat atlas [25] 
RESULTS
Changes in blood glucose levels: In the pre-diabetic stages, the blood glucose levels were similar between vehicle-and STZ-treated groups (5.81 mmol/L and 5.83 mmol/L, respectively). In the vehicle-treated group, the blood glucose level did not change significantly 4 weeks after vehicle treatment. However, in the STZ-treated group, blood glucose level significantly increased at 2 weeks after STZ treatment compared to the vehicle-treated counterpart and higher blood glucose levels were maintained 4 weeks after STZ treatment. At 3 weeks after STZ treatment, the blood glucose peaked and slightly decreased 4 weeks after STZ treatment (Fig. 1) .
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Changes in COX-2 immunoreactivity: COX-2 immunoreactivity was mainly detected in the granule cells and some interneurons in polymorphic layer of dentate gyrus in all groups (Fig. 2) . However, there were significant differences in COX-2 immunoreactivity in dentate gyrus between groups. In the vehicle-treated groups, there were no significant changes with time after treatment (data not shown). At 4 weeks after vehicle treatment, COX-2 immunoreactivity was detected mainly in the granule cell layer of the dentate gyrus ( Fig. 2A) . At 2 weeks after STZ treatment, COX-2 immunoreactivity was slightly increased in the dentate gyrus compared to that in the control group ( Fig. 2B and 2E ). At 3 weeks after STZ treatment, COX-2 immunoreactivity was significantly increased in the dentate gyrus compared to the control or 2 weeks post-STZ group (Fig. 2C and   2E ). At 4 weeks after STZ treatment, COX-2 immunoreactivity was significantly decreased in the dentate gyrus compared to that in the 2 or 3 weeks post-STZ group and slightly low compared to that in the control group (Fig. 2D and 2E ). COX-2 immunoreactivity was mainly detected in the stratum pyramidale of CA3 region (Fig. 3) . However, there were no significant differences in COX-2 immunoreactivity in CA3 region between groups (Fig. 3 ).
DISCUSSION
Diabetic brain shows cognitive deficits and increased risk of developing dementia,
FULL PAPER, Anatomy 9 especially the incidence of Alzheimer's disease [18] . In a previous study, the MRI differences in brain lesions between the two type diabetes were compared and more prominent cognitive disturbances were found in type 2 DM [3] . In particular, hippocampus-based memory impairments and cognitive dysfunction are reported in both type of DM [1, 10] . In non-obese, type 1 DM mice, reduction of hippocampal neurogenesis is reported [2] and in our previous report with STZinduced type 1 DM rats, that pattern was also observed [5] .
In this study, we investigated COX-2 immunoreactivity in the dentate gyrus and hippocampal CA3 region in diabetic rats. There were some differences in expression of COX-2 between vehicle-treated control and STZ-treated diabetic animals. COX-2 immunoreactivity was significantly increased in the dentate gyrus, not CA3 region, after STZ treatment, but after this period, the increase pattern was conversed.
The changes of COX-2 immunoreactivity in the dentate gyrus, not CA3 region may be associated with the neurogenesis occurred in the dentate gyrus. COX-2's action is involved with various prostaglandins [28] , cell cycle proteins [23] and the NMDA receptor [19] . Still, COX-2's roles in neurogenesis are not fully elucidated and it can behave like a double-edged sword with positive or negative effect. One of possible actions of COX-2 is on cell cycle proteins. COX-2 showed a positive effect on proliferation of neural progenitor cells and synaptic plasticity [28] . COX-2 inhibition is related with memory impairment and COX-2 knockouts showed reduced hippocampal neurogenesis [31] . In our previous study, we reported that STZ significantly increased latency time in a Morris water maze test FULL PAPER, Anatomy 10 and doublecortin immunoreactive neuroblasts were significantly decreased 2-3 weeks after STZ treatment [5] . However, in the present study, we observed the decrease of COX-2 immunoreactivity in the dentate gyrus at 4 weeks after STZ treatment. This result was coincided with previous study that doublecortin immunoreactive neuroblasts were increased at 4 weeks after STZ treatment [5] . It has been reported that neurogenesis is transiently increased in brain damage such as ischemia [6, 14, 30, 33] . In type 2 diabetic rats, we reported that diabetes significantly reduced cell proliferation, neuroblast differentiation and COX-2 levels in the dentate gyrus [12, 13] . In addition, the blockade of COX-2 by celecoxib significantly ameliorated the reduction of neuroblast differentiation [13] .
Our results strongly suggest that the action of COX-2 is related to neuroblast differentiation in the dentate gyrus.
Another possible action of COX-2 is the pro-inflammatory effect. In STZinduced diabetic animals, insulin treatment resulted in reduced ischemia and reperfusion injury with decreased expression of nuclear factor-κB, COX-2 and inducible nitric oxide synthase [7] . In alcohol-induced brain damage, COX-2 was induced and its pattern was similar to that induced by excitatory amino acids [19] , and COX-2 induction was also observed after seizure in rats [34] . Increased expression of COX-2 is reported to be related with reactive oxygen species and neuronal oxidative stress [22] . Alteration of the COX-2 pathway and oxidative stress was reported to being related with diabetic neuropathy [16] . In the present study, we also observed transient increase of COX-2 immunoreactivity in the dentate gyrus.
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In conclusion, after STZ treatment, a type 1 diabetic-like state was induced in rats and COX-2 immunoreactivity was transiently increased in the dentate gyrus, not hippocampal CA3 region, 2-3 weeks after STZ treatment. These increases of COX-2 immunoreactivity may be associated with reduction of neural plasticity in the dentate gyrus. There are no significant differences between groups. The bars indicate the SEM. 
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